Approval

Approval  ·  Weekly Digest - 21 March to 27 March 2026
Chugai obtains regulatory approval for Lunsumio and Polivy combination therapy for additional indication of relapsed or refractory large b-cell lymphoma

Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: Chugai obtains regulatory approval for Lunsumio and Polivy combination therapy for additional indication of relapsed or refractory large b-cell lymphoma Chugai has received approval in Japan (MHLW) […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 07 February to 13 February 2026
Kelun-Biotech announces fourth indication for Sacituzumab Tirumotecan (sac-TMT) approved by NMPA in HR+/HER2- breast cancer

Weekly Digest – February 2026 Weekly Digest – February 2026 06 February 2026: Kelun-Biotech announces fourth indication for Sacituzumab Tirumotecan (sac-TMT) approved by NMPA in HR+/HER2- breast cancer Sichuan Kelun-Biotech announced that China’s National Medical Products Administration has approved a […]

by Sandhya Ramalingam

Continue Reading